Bachem Announces Progress in Building K Start-Up and Expansion of Its Site in Vista, CA

Bachem, a prominent player in peptide and oligonucleotide manufacturing, recently announced significant advancements in its capacity expansion projects. The latest update, dated October 23, 2025, reveals that the inspection of Building K in Bubendorf, Switzerland, has been successfully completed by local regulatory authorities, with no delays anticipated in the development timeline. Bachem aims to commence production of the first Good Manufacturing Practice (GMP) batches in 2025, while ramping up commercial production in 2026. The construction in the remainder of Building K will continue concurrently.

In addition to developments in Bubendorf, Bachem has acquired an adjacent property to its existing facility in Vista, California. This acquisition is pivotal for future capacity expansions and will facilitate the transformation of the new property into an operational production facility. Bachem has outlined a robust investment plan of approximately USD 250 million from 2026 to 2030, targeting enhancements at both the Vista site and the modernization of its Torrance facility.

Bachem's CEO, Thomas Meier, expressed excitement over the progress in their capacity expansions, emphasizing that Building K is not just their largest project but also one of the most advanced peptide manufacturing facilities globally, expected to employ around 350 people to produce multiple tons of peptides annually. This growth strategically positions Bachem to increase its footprint in the U.S. healthcare market, thereby bolstering its commercial partnerships.

As a leading innovation-driven firm specializing in peptide and oligonucleotide manufacturing, Bachem operates internationally and has over 50 years of industry experience. It is listed on the SIX Swiss Exchange and is recognized for its extensive service offerings to pharmaceutical and biotechnology companies. More information about the company can be found at www.bachem.com.

Bachem’s recent announcements regarding its capacity expansion initiatives in Bubendorf and Vista, California, underscore a solid trajectory for growth that positions the company advantageously in the peptide and oligonucleotide manufacturing sector. With the inspection of Building K passing without delays, Bachem is on course to begin production of Good Manufacturing Practice (GMP) batches by 2025, highlighting the company's operational efficiency and regulatory compliance.

The capacity investments of approximately USD 250 million in the U.S. signal a robust commitment to bolstering its infrastructure in the world’s largest healthcare market. The acquisition of additional property in Vista is particularly strategic, as it allows for the expansion of production capabilities, which is crucial for meeting increasing global demand for peptide products.

From a market perspective, Bachem's proactive approach to expansion not only enhances its manufacturing capabilities but also strengthens its market position against competitors. As the demand for peptide therapeutics continues to rise, Bachem is well-poised to capture a larger share of the market given its planned ramp-up in production capacity.

Investors should consider Bachem’s expansion efforts as a potential catalyst for future growth. The establishment of one of the most modern production facilities globally at Bubendorf, combined with the strategic development in Vista, suggests that Bachem is not just responding to current market demands but is also anticipating future needs, enabling long-term sustainability and revenue growth.

Overall, Bachem’s proactive capacity expansion strategy, attributed to its strong leadership and vision for the future, presents a compelling investment opportunity, particularly in a sector characterized by rapid development and increasing commercialization of therapeutic peptides. Market players should monitor Bachem's progress closely as it approaches these significant milestones.